study

The evidence presented in this review allows us to conclude that Δ9-THC and CBD produce biphasic, dose-dependent effects on several physiological responses. The biphasic nature of cannabinoid effects highlights the need for a careful analysis of the dose ranges separating therapeutic from unwanted effects. Besides, Δ9-THC produces dependence and harmful effects, while CBD does not.
The available pharmaceutical formulations of these phytocannabinoids and related molecules have clear therapeutic effects; however, more research is needed to assure their efficacy and safety since their effects are complex. Several additional potential therapeutic applications, mainly for CBD, are being proposed which, however, still lack sufficient clinical and preclinical support. For this reason, caution is advised when using or prescribing cannabinoids.
Additional consideration deserves the fact that the ECS participates in the development of the central nervous system98. Therefore, the use of cannabinoid-based formulations for the medical treatment of children and adolescents experiencing brain developmental changes must be carefully examined, balancing the pros and cons of prescribing cannabinoid-based medications in every single case. Cannabis research field is expanding with the identification of new molecular targets, the characterization of undescribed phytocannabinoids, and novel findings related to the ECS99. In addition, consumption of synthetic cannabinoids as drugs of abuse represents a new challenge in addiction research100.

There are numerous examples of the relationship between treatment expectations and placebo responses. If a person thinks they will experience relief from their pain by using a certain product or treatment, this can change the way they end up perceiving incoming pain signals – making them think their pain is less severe. Recent evidence suggests that the placebo effect may work even if we're presented with evidence that contradicts our initial expectations.
We cannot say with 100 percent certainty that media coverage is responsible for the high placebo response observed in our review. But given placebos were shown to be just as good as cannabis for managing pain, our results show just how important it is to think about the placebo effect and how it can be influenced by external factors – such as media coverage.

Conclusions: This is the first characterization of the effect of cannabis exposure on the entirety of the rat sperm methylome. We identified CE-associated methylation changes across the sperm methylome, some of which persisted despite a "washout" period. Select methylation changes validated via bisulfite pyrosequencing, and genes associated with methylation changes were involved in early developmental processes. Preconception CE exposure is associated with detectable changes in offspring DNA methylation that are functionally related to changes in gene expression and cardiomegaly. These results support that paternal preconception exposure to cannabis can influence offspring outcomes.     

Like CBD, delta-8 (delta-8 tetrahydrocannabinol) is just one of more than 100 chemical compounds found in the cannabis sativa plant. Most people are familiar with THC (delta-9 tetrahydrocannabinol), the main psychoactive compound in cannabis that gives you a euphoric high.
The 2018 Farm Bill legalized the production and sale of CBD products (which don’t get you high) on the federal level in the U.S. as long as they contain less than .3% of THC. In theory, this would allow federal legalization of CBD products with delta-8 under those same guidelines, but doctors, like internal medicine specialist Paul Terpeluk, DO, are expressing concerns about delta-8 products because delta-8 is psychoactive and produces same or similar highs as THC.

Conclusions
Findings provide initial insight into the current state of Delta-8 THC use in the US. Given the limited knowledge on use of Delta-8 THC, and considering emergence of reports indicating its harmful effects, there is urgent need for nationally representative data to investigate correlates of Delta-8 THC use (e.g., effectiveness of state-specific restrictions on its products). Such information can guide public-health policy around Delta-8 THC use.

An analysis of survey data from more than 280,000 young adults ages 18-35 showed that cannabis (marijuana) use was associated with increased risks of thoughts of suicide (suicidal ideation), suicide plan, and suicide attempt. These associations remained regardless of whether someone was also experiencing depression, and the risks were greater for women than for men.
“Suicide is a leading cause of death among young adults in the United States, and the findings of this study offer important information that may help us reduce this risk,”

In conclusion, our findings confirm previous evidence of the harmful effect on mental health of daily use of cannabis, especially of high-potency types. Importantly, they indicate for the first time how cannabis use affects the incidence of psychotic disorder. Therefore, it is of public health importance to acknowledge alongside the potential medicinal properties of some cannabis constituents the potential adverse effects that are associated with daily cannabis use, especially of high-potency varieties.

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an earlier age than children of non-using mothers, according to a new study from the Harvard T.H. Chan School of Public Health published in the American Journal of Preventive Medicine. This study is the first to establish a relationship between maternal cannabis use during a child's lifetime and earlier initiation in a nationally-representative, longitudinal cohort and examine the role of race, gender, and other social environmental factors.

We found that among young recreational cannabis users, a regular dose of cannabis had no effect on simple and learned tasks, but its use led to significant impairments on complex and novel driving-related tasks, as well as perceived driving ability and safety, for up to 5 hours after use. The present finding that the first 5 hours after cannabis use affected driving-related performance substantiates the recommendations of Canada’s Lower-Risk Cannabis Use Guidelines, which recommend waiting 6 hours after cannabis use before driving.30
 

Conclusions: Our findings disconfirm the hypothesis that a population-level negative correlation between medical marijuana use and prescription drug harms occurs because medical marijuana users are less likely to use prescription drugs, either medically or nonmedically. Medical marijuana users should be a target population in efforts to combat nonmedical prescription drug use.

Cryptococcal meningitis in a daily cannabis smoker without evidence of immunodeficiency.
Cryptococcal meningitis is a life-threatening condition most commonly observed in immunocompromised individuals. We describe a daily cannabis smoker without evidence of immunodeficiency presenting with confirmed Cryptococcus neoformans meningitis. An investigation of cannabis samples from the patient's preferred dispensary demonstrated contamination with several varieties of Cryptococcus, including C. neoformans, and other opportunistic fungi. These findings raise concern regarding the safety of dispensary-grade cannabis, even in immunocompetent users.

The main finding was that when rats were exposed to secondhand smoke from marijuana for one minute, their arteries became less efficient at carrying enough blood for at least 90 minutes, whereas similar exposure to secondhand smoke from tobacco caused impairment that fully recovered within 30 minutes (exposure to clean air in the exposure chamber did not cause impairment). (It is important to understand that arteries of rats and humans are similar in how they respond to tobacco smoke, so the response of rat arteries to marijuana smoke is expected to be a valid indication of how human arteries respond to marijuana smoke.)

Abstract

Contemporary models of substance use disorders emphasize the role of cognitive control, which has been linked to difficulties in resisting the use of substances. In the present study, we measured two aspects of cognitive control, response inhibition (operationalized by a Go/NoGo Task) and performance monitoring (operationalized by an Eriksen Flanker Task), in a group of young cannabis-use disorder (CUD) patients and compared these functions with two control groups (i.e. a group of cigarette smokers and a group of non-smokers). We employed both behavioural and electrophysiological measures. The results indicate that CUD patients displayed reduced NoGo-P3 event-related potentials compared with non-smoking controls, but not compared with smoking controls. In addition, CUD patients were slower on Go trials than both control groups. No other between-group electrophysiological or behavioural differences were observed. These results seem to suggest that CUD patients have problems related to response inhibition, but performance monitoring seems relatively unaffected.

Conclusions One-fifth of the adolescents in our sample followed a pattern of occasional or regular cannabis use, and these young people were more likely to progress to harmful substance use behaviors in early adulthood.

UC Davis physician researchers have found that medical marijuana contains multiple bacterial and fungal pathogens that may cause serious and even fatal infections. They warn that smoking, vaping or inhaling aerosolized marijuana could pose a grave risk to patients, especially those with leukemia, lymphoma, AIDS or conditions requiring immune-suppressing therapies.
 
“Infection with the pathogens we found in medical marijuana could lead to serious illness and even death,” said Joseph Tuscano, a professor of internal medicine in the Division of Hematology and Oncology at UC Davis, and a lead study author. “Inhaling marijuana in any form provides a direct portal of entry deep into the lungs where infection can easily take hold.”